Treatment targets in IBD: is it time for new strategies?

F D'Amico has served as a speaker for Abbvie, Sandoz, Janssen, Galapagos, Omega Pharma, Takeda and Tillotts; he also served as consultant for Ferring and as advisory board member for Galapagos, Abbvie, Ferring, Takeda, and Nestlè. S Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millennium Takeda, MSD, Nikkiso Europe

Comments (0)

No login
gif